title: Prognostic importance of the soluble form of IL-2 receptorα (sIL-2Rα) and its relationship with surface expression of IL-2Rα (CD25) of lymphoma cells in diffuse large B-cell lymphoma treated with CHOP-like regimen with or without rituximab: a retrospective analysis of 338 cases.
abstract: We evaluated the prognostic significance of the serum level of the soluble form of interleukin-2 receptorα (sIL-2Rα) and investigated its association with CD25 expression on tumor cells in diffuse large B-cell lymphoma (DLBCL). Three hundred and thirty-eight adult patients with newly diagnosed DLBCL were eligible for this retrospective study. 32.2% of patients were treated with CHOP-like regimen and 67.8% with R-CHOP-like regimen. CD25 expression on the surface of tumor cells was evaluated in 143 cases and its relationship with sIL-2Rα level was also investigated. Both overall survival (OS) and progression-free survival (PFS) were poorer in patients with higher sIL-2Rα, in both R-CHOP and CHOP groups. sIL-2Rα > 1,000 U/mL and performance status (PS) ≥ 2 were independently associated with poorer OS, and sIL-2Rα > 1,000 U/mL, age > 60 years, and ≥ 2 extranodal sites were independently associated with poorer PFS in the R-CHOP group. The sIL-2Rα level was higher in the CD25-positive group than in the CD25-negative group in stage 3 or 4 disease (p = 0.010). Multiple linear regression analysis showed CD25 expression to be independently correlated with sIL-2Rα levels. High sIL-2Rα is an important risk factor for survival in DLBCL treated with not only CHOP-like, but also R-CHOP-like regimens, regardless of the tumor's expression of CD25.
authors.affiliation: Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine.
authors.forename: Yoko
authors.initials: Y
authors.lastname: Hashimoto
authors.forename: Akihiko
authors.initials: A
authors.lastname: Yokohama
authors.forename: Akio
authors.initials: A
authors.lastname: Saitoh
authors.forename: Hirotaka
authors.initials: H
authors.lastname: Nakahashi
authors.forename: Kohtaro
authors.initials: K
authors.lastname: Toyama
authors.forename: Takeki
authors.initials: T
authors.lastname: Mitsui
authors.forename: Hiromi
authors.initials: H
authors.lastname: Koiso
authors.forename: Takayuki
authors.initials: T
authors.lastname: Saitoh
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Handa
authors.forename: Hideki
authors.initials: H
authors.lastname: Uchiumi
authors.forename: Takahiro
authors.initials: T
authors.lastname: Jinbo
authors.forename: Kayoko
authors.initials: K
authors.lastname: Murayama
authors.forename: Morio
authors.initials: M
authors.lastname: Matsumoto
authors.forename: Morio
authors.initials: M
authors.lastname: Sawamura
authors.forename: Masamitsu
authors.initials: M
authors.lastname: Karasawa
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Murakami
authors.forename: Junko
authors.initials: J
authors.lastname: Hirato
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Nojima
authors.forename: Masaru
authors.initials: M
authors.lastname: Kojima
authors.forename: Norifumi
authors.initials: N
authors.lastname: Tsukamoto
mesh_terms: D000328:Adult; D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D053645:Interleukin-2 Receptor alpha Subunit / Q000097:blood / Q000378:metabolism*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D012189:Retrospective Studies; D000069283:Rituximab; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D053645:Interleukin-2 Receptor alpha Subunit; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone